Denosumab: The Antibody That Stops Bone-Eating Cells but Can't Be Stopped Easily

Denosumab (brand names Prolia, Xgeva) is a fully human monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand) — a signaling protein essential for the formation, function, and survival of Osteoclasts: The Bone-Resorbing Cells. ## How It Works By blocking RANKL, denosumab dramatically reduces bone resorption, increasing bone mineral density. It is administered as a 60 mg subcutaneous injection every 6 months for Osteoporosis: When Bone Breakdown Outpaces Bone Building, or at higher doses (Xgeva, 120 mg monthly) for bone metastases. ## Clinical Performance Denosumab showed greater BMD gains than Bisphosphonates: The First-Line Defense Against Osteoporosis in some clinical trials and has proven effective in reducing hip, vertebral, and non-vertebral fractures. ## The Rebound Problem The critical clinical concern: discontinuing denosumab causes a rapid surge in RANKL activity, triggering accelerated bone resorption that can result in **multiple vertebral fractures** in some patients. The rebound effect occurs because denosumab doesn't accumulate in bone (unlike bisphosphonates, which persist for years). For this reason, discontinuation must be managed by transitioning to a bisphosphonate to maintain the bone-protective effect. ## Side Effects Hypocalcemia (especially in vitamin D-deficient patients) and a small risk of osteonecrosis of the jaw — similar to bisphosphonates.